UK markets open in 3 hours 46 minutes
  • NIKKEI 225

    29,375.94
    +214.14 (+0.73%)
     
  • HANG SENG

    28,483.87
    -358.26 (-1.24%)
     
  • CRUDE OIL

    71.02
    +0.14 (+0.20%)
     
  • GOLD FUTURES

    1,863.10
    -2.80 (-0.15%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • BTC-GBP

    28,640.34
    +977.13 (+3.53%)
     
  • CMC Crypto 200

    1,009.73
    +40.89 (+4.22%)
     
  • ^IXIC

    14,174.14
    +104.72 (+0.74%)
     
  • ^FTAS

    4,074.57
    +6.24 (+0.15%)
     

AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively.

During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA will discuss the Company’s corporate strategy and precision medicine approach, while highlighting its clinical-stage Alzheimer’s disease vaccine programs targeting phospho-Tau and Abeta. Details of the upcoming presentations are shown below.

UBS Global Healthcare Virtual Conference
Date: May 26, 2021 | 7:00 – 7:45 am ET / 1:00 – 1:45 pm CET
Format: Corporate presentation

Jefferies Virtual Healthcare Conference
Date: June 2, 2021 | 8:00 – 8:25 am ET / 2:00 – 2:25 pm CET
Format: Fireside chat

A webcast of the corporate presentation and fireside chat will be available on the Events Page of AC Immune’s website.

About AC Immune SA
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigenTM and MorphomerTM, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

For further information, please contact:

Head of Investor Relations and
Corporate Communications
Joshua Drumm, Ph.D.
AC Immune
Phone : +1 917 809 0814
Email: joshua.drumm@acimmune.com

U.S. Media
Katie Gallagher
LaVoie Health Science
Phone: +1 617 792 3937
Email: kgallagher@lavoiehealthscience.com

European Investors & Media
Chris Maggos
LifeSci Advisors
Phone : +41 79 367 6254
Email : chris@lifesciadvisors.com

Forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.